|
PL3412676T3
(pl)
|
2010-08-10 |
2021-04-06 |
Melinta Therapeutics, Inc. |
Cykliczne pochodne estrowe kwasu boronowego, sposób otrzymywania oraz ich zastosowania terapeutyczne
|
|
WO2012088266A2
(en)
|
2010-12-22 |
2012-06-28 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
|
|
EP2487159A1
(en)
|
2011-02-11 |
2012-08-15 |
MSD Oss B.V. |
RorgammaT inhibitors
|
|
WO2013033461A1
(en)
|
2011-08-31 |
2013-03-07 |
Rempex Pharmaceuticals, Inc. |
Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
|
|
WO2013064231A1
(en)
|
2011-10-31 |
2013-05-10 |
Phenex Pharmaceuticals Ag |
SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
|
|
US9815851B2
(en)
|
2011-12-02 |
2017-11-14 |
Phenex Pharmaceuticals Ag |
Pyrrolo carboxamides as modulators of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
|
|
WO2013169864A2
(en)
*
|
2012-05-08 |
2013-11-14 |
Lycera Corporation |
TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
|
|
MX367341B
(es)
*
|
2012-05-08 |
2019-08-14 |
Merck Sharp & Dohme |
Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
|
|
US9156858B2
(en)
|
2012-05-23 |
2015-10-13 |
Rempex Pharmaceuticals, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
NZ702539A
(en)
|
2012-05-31 |
2016-11-25 |
Phenex Pharmaceuticals Ag |
Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
|
|
US10561675B2
(en)
|
2012-06-06 |
2020-02-18 |
Rempex Pharmaceuticals, Inc. |
Cyclic boronic acid ester derivatives and therapeutic uses thereof
|
|
LT3495367T
(lt)
|
2012-06-13 |
2021-02-25 |
Incyte Holdings Corporation |
Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
|
|
JO3215B1
(ar)
|
2012-08-09 |
2018-03-08 |
Phenex Pharmaceuticals Ag |
حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
|
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
|
WO2014026329A1
(en)
*
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
|
|
WO2014026328A1
(en)
*
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
|
|
WO2014026327A1
(en)
*
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
|
|
WO2014026330A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
KR20150103270A
(ko)
|
2013-01-04 |
2015-09-09 |
렘펙스 파머수티클스 인코퍼레이티드 |
보론산 유도체 및 그의 치료적 용도
|
|
EP2941246A4
(en)
|
2013-01-04 |
2016-12-21 |
Rempex Pharmaceuticals Inc |
BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
|
|
US9101638B2
(en)
|
2013-01-04 |
2015-08-11 |
Rempex Pharmaceuticals, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
US9241947B2
(en)
|
2013-01-04 |
2016-01-26 |
Rempex Pharmaceuticals, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
LT2986610T
(lt)
|
2013-04-19 |
2018-04-10 |
Incyte Holdings Corporation |
Bicikliniai heterociklai, kaip fgfr inhibitoriai
|
|
EP3027616B1
(en)
*
|
2013-07-30 |
2018-01-10 |
Boehringer Ingelheim International GmbH |
Azaindole compounds as modulators of rorc
|
|
JP6501782B2
(ja)
*
|
2013-09-05 |
2019-04-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｒｏｒガンマのモジュレーターとしての二環式化合物
|
|
US9550771B2
(en)
*
|
2013-09-11 |
2017-01-24 |
Genentech, Inc. |
Keto-imidazopyridine derivatives as RORc modulators
|
|
US10555941B2
(en)
|
2013-10-15 |
2020-02-11 |
Janssen Pharmaceutica Nv |
Alkyl linked quinolinyl modulators of RORγt
|
|
CN105873439A
(zh)
*
|
2013-10-15 |
2016-08-17 |
詹森药业有限公司 |
RORγt的烷基连接的喹啉基调节剂
|
|
US9403816B2
(en)
|
2013-10-15 |
2016-08-02 |
Janssen Pharmaceutica Nv |
Phenyl linked quinolinyl modulators of RORγt
|
|
KR20160068948A
(ko)
*
|
2013-10-15 |
2016-06-15 |
얀센 파마슈티카 엔.브이. |
RORyt의 이차 알코올 퀴놀리닐 조절제
|
|
KR20160068956A
(ko)
|
2013-10-15 |
2016-06-15 |
얀센 파마슈티카 엔.브이. |
RORyT의 퀴놀리닐 조절제
|
|
TW201605797A
(zh)
*
|
2013-12-10 |
2016-02-16 |
葛蘭馬克製藥公司 |
作為ror伽馬調節物的雙環雜芳基化合物
|
|
CN104530014B
(zh)
*
|
2013-12-25 |
2018-03-20 |
中国科学院广州生物医药与健康研究院 |
2‑氧代‑1,2‑二氢苯并[cd]吲哚‑6‑磺酰胺类化合物及其组合物和应用
|
|
WO2015101928A1
(en)
*
|
2013-12-31 |
2015-07-09 |
Aurigene Discovery Technologies Limited |
Fused thiophene and thiazole derivatives as ror gamma modulators
|
|
EP3527569B1
(en)
|
2014-02-03 |
2021-08-25 |
Vitae Pharmaceuticals, LLC |
Dihydropyrrolopyridine inhibitors of ror-gamma for use in treating drye eye
|
|
AU2015222917A1
(en)
|
2014-02-27 |
2016-09-15 |
Lycera Corporation |
Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
|
|
WO2015139621A1
(zh)
*
|
2014-03-18 |
2015-09-24 |
北京韩美药品有限公司 |
4-杂芳基取代的苯甲酸或苯甲酰胺类化合物
|
|
US9687497B1
(en)
|
2014-05-05 |
2017-06-27 |
Rempex Pharmaceuticals, Inc. |
Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
|
|
EP3140310B1
(en)
|
2014-05-05 |
2019-08-07 |
Rempex Pharmaceuticals, Inc. |
Synthesis of boronate salts and uses thereof
|
|
JP6728061B2
(ja)
|
2014-05-05 |
2020-07-22 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療
|
|
JP6523337B2
(ja)
|
2014-05-05 |
2019-05-29 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
|
|
AU2015264418A1
(en)
|
2014-05-19 |
2016-11-10 |
Rempex Pharmaceuticals, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
US10206937B2
(en)
|
2014-07-01 |
2019-02-19 |
Qpex Biopharma, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
TWI675032B
(zh)
|
2014-10-14 |
2019-10-21 |
美商維它藥物公司 |
ＲＯＲ-γ之二氫吡咯并吡啶抑制劑
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
GB201419015D0
(en)
|
2014-10-24 |
2014-12-10 |
Orca Pharmaceuticals Ltd |
Compounds
|
|
US9663515B2
(en)
|
2014-11-05 |
2017-05-30 |
Vitae Pharmaceuticals, Inc. |
Dihydropyrrolopyridine inhibitors of ROR-gamma
|
|
US9845308B2
(en)
|
2014-11-05 |
2017-12-19 |
Vitae Pharmaceuticals, Inc. |
Isoindoline inhibitors of ROR-gamma
|
|
WO2016081297A1
(en)
|
2014-11-18 |
2016-05-26 |
Rempex Pharmaceuticals, Inc. |
Cyclic boronic acid ester derivatives and therapeutic uses thereof
|
|
CA2973185C
(en)
*
|
2015-01-08 |
2021-02-16 |
Advinus Therapeutics Limited |
Bridgehead nitrogen bicyclic inhibitors/modulators of retinoic acid-related orphan receptor gamma (ror.gamma.)
|
|
WO2016130818A1
(en)
*
|
2015-02-11 |
2016-08-18 |
Merck Sharp & Dohme Corp. |
SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
|
|
WO2016128908A1
(en)
|
2015-02-12 |
2016-08-18 |
Advinus Therapeutics Limited |
Bicyclic compounds, compositions and medicinal applications thereof
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
SG11201706287PA
(en)
|
2015-02-20 |
2017-09-28 |
Incyte Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN107614062A
(zh)
|
2015-03-12 |
2018-01-19 |
加利福尼亚大学董事会 |
用RORγ抑制剂治疗癌症的方法
|
|
US20180051041A1
(en)
|
2015-03-17 |
2018-02-22 |
Rempex Pharmaceuticals, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
US10849992B1
(en)
*
|
2015-04-07 |
2020-12-01 |
Alector Llc |
Methods of screening for sortilin binding antagonists
|
|
AU2016257997A1
(en)
|
2015-05-05 |
2017-11-09 |
Lycera Corporation |
Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
|
|
WO2016198908A1
(en)
*
|
2015-06-09 |
2016-12-15 |
Abbvie Inc. |
Ror nuclear receptor modulators
|
|
HUE047988T2
(hu)
*
|
2015-06-09 |
2020-05-28 |
Abbvie Inc |
Nukleáris receptor modulátorok (ROR) gyulladásos és autoimmun betegségek kezelésére
|
|
US10611740B2
(en)
|
2015-06-11 |
2020-04-07 |
Lycera Corporation |
Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
|
|
ES2856931T3
(es)
|
2015-08-05 |
2021-09-28 |
Vitae Pharmaceuticals Llc |
Moduladores de ROR-gamma
|
|
EP4071149A3
(en)
*
|
2015-09-21 |
2023-01-25 |
Opna Immuno Oncology, SA |
Heterocyclic compounds and uses thereof
|
|
US10344000B2
(en)
|
2015-10-27 |
2019-07-09 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
|
|
WO2017075185A1
(en)
*
|
2015-10-27 |
2017-05-04 |
Merck Sharp & Dohme Corp. |
Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
|
|
WO2017075182A1
(en)
*
|
2015-10-27 |
2017-05-04 |
Merck Sharp & Dohme Corp. |
Substituted indazole compounds as rorgammat inhibitors and uses thereof
|
|
EP3868750A1
(en)
|
2015-11-20 |
2021-08-25 |
Vitae Pharmaceuticals, LLC |
Modulators of ror-gamma
|
|
CN105412929B
(zh)
*
|
2015-11-27 |
2018-03-20 |
肖定璋 |
Il7r‑3’utr在调控维甲酸相关孤儿核受体表达中的应用
|
|
TWI728017B
(zh)
|
2015-12-15 |
2021-05-21 |
瑞典商阿斯特捷利康公司 |
異吲哚化合物、包含其之醫藥組成物及其用途
|
|
US10793566B2
(en)
|
2016-01-21 |
2020-10-06 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
|
CA3009669C
(en)
*
|
2016-01-21 |
2023-08-08 |
Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. |
Bruton's tyrosine kinase inhibitors
|
|
TW202220968A
(zh)
|
2016-01-29 |
2022-06-01 |
美商維它藥物有限責任公司 |
ＲＯＲ－γ調節劑
|
|
US9481674B1
(en)
|
2016-06-10 |
2016-11-01 |
Vitae Pharmaceuticals, Inc. |
Dihydropyrrolopyridine inhibitors of ROR-gamma
|
|
MY196909A
(en)
|
2016-06-30 |
2023-05-09 |
Qpex Biopharma Inc |
Boronic acid derivatives and therapeutic uses thereof
|
|
WO2018084120A1
(ja)
*
|
2016-11-01 |
2018-05-11 |
学校法人東京理科大学 |
安息香酸誘導体及び脱水縮合剤、並びにエステル及びラクトンの製造方法
|
|
JP2020111510A
(ja)
*
|
2017-03-29 |
2020-07-27 |
科研製薬株式会社 |
インダゾール誘導体及びそれを含有する医薬
|
|
JP7090639B2
(ja)
|
2017-04-11 |
2022-06-24 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッド |
フッ素置換されたインダゾール化合物及びその使用
|
|
IT201700041723A1
(it)
|
2017-04-14 |
2018-10-14 |
Italfarmaco Spa |
Nuovi inibitori selettivi di HDAC6
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
KR20200019176A
(ko)
*
|
2017-06-12 |
2020-02-21 |
싸이프러스 바이오-테크 컴퍼니 리미티드 |
다중-적용 곤충 기피제 첨가제
|
|
EP3638661A1
(en)
|
2017-06-14 |
2020-04-22 |
Astrazeneca AB |
2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
|
|
WO2019018975A1
(en)
|
2017-07-24 |
2019-01-31 |
Vitae Pharmaceuticals, Inc. |
INHIBITORS OF ROR GAMMA
|
|
MA49685A
(fr)
|
2017-07-24 |
2021-04-14 |
Vitae Pharmaceuticals Llc |
INHIBITEURS DE ROR gamma
|
|
CN109485595B
(zh)
*
|
2017-09-12 |
2022-05-27 |
江苏恒瑞医药股份有限公司 |
亲水性基团取代的吲哚甲酰胺类衍生物、其制备方法及其在医药上的应用
|
|
EP3694864B1
(en)
|
2017-10-11 |
2025-03-05 |
Qpex Biopharma, Inc. |
Boronic acid derivatives and synthesis thereof
|
|
US10508113B2
(en)
|
2018-03-12 |
2019-12-17 |
Abbvie Inc. |
Inhibitors of tyrosine kinase 2 mediated signaling
|
|
AU2019256351B2
(en)
|
2018-04-20 |
2024-02-29 |
Qpex Biopharma, Inc. |
Boronic acid derivatives and therapeutic uses thereof
|
|
ES3061844T3
(en)
|
2018-05-04 |
2026-04-07 |
Incyte Corp |
Salts of an fgfr inhibitor
|
|
MX2020011718A
(es)
|
2018-05-04 |
2021-02-15 |
Incyte Corp |
Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US12122767B2
(en)
|
2019-10-01 |
2024-10-22 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2021113462A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Derivatives of an fgfr inhibitor
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US12552815B2
(en)
|
2020-05-05 |
2026-02-17 |
Qpex Biopharma, Inc. |
Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
JP2024522189A
(ja)
|
2021-06-09 |
2024-06-11 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤としての三環式ヘテロ環
|
|
EP4352060A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2023232870A1
(en)
|
2022-05-31 |
2023-12-07 |
Immunic Ag |
Rorg/rorgt modulators for the treatment of virus infections like covid-19
|